Overview

Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This study will assess the efficacy of daratumumab in combination with ixazomib and dexamethasone as second line treatment for relapsed Multiple Myeloma patients.

Phase:

Phase 2

Details

Lead Sponsor:

Hellenic Society of Hematology

Collaborators:

Janssen Pharmaceutica NV
Takeda
Takeda Pharmaceuticals Company Ltd.

Treatments:

Antibodies, Monoclonal
BB 1101
Daratumumab
Dexamethasone
Dexamethasone acetate
Glycine
Ixazomib